Keywords: ImmunoGen, Novartis, Antibodies, TA technology, Licensing, Financial update, Cancer drugs

ImmunoGen collaborates with Novartis on cancer drugs for $45 million upfront, plus potential $200 million per target; updates financials

Article | 12 October 2010

Print This

US drug developer ImmunoGen (Nasdaq: IMGN) says that it has entered into a collaboration agreement with Novartis (NOVN: VX) to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in